|
Hyperlipidemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.
|
21619378 |
2011 |
|
Hyperlipidemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
To provide superior individualized care for patients with hyperlipidemia, there is a potential role for newer therapies in lipid lowering, such as PCSK9 inhibitors, in appropriate high-risk populations.
|
29172973 |
2017 |
|
Hyperlipidemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook.
|
28424973 |
2017 |
|
Hyperlipidemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been approved for treating hyperlipidemia in these patients.
|
30280628 |
2019 |
|
Hyperlipidemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Contribution of aorta glycosaminoglycans and PCSK9 to hyperlipidemia in experimental rabbits: the role of 10-dehdrogingerdione as effective modulator.
|
31049833 |
2019 |
|
Hyperlipidemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Assessment and Management of Patients with Hyperlipidemia Referred for Initiation of PCSK9 Inhibitor Therapy: A Lipid Clinic Experience.
|
31119582 |
2019 |
|
Hyperlipidemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
This study was designed to determine whether PCSK9 is crucial between hyperlipidemia and Alzheimer's disease.
|
28304296 |
2017 |
|
Hyperlipidemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Among 122 anti-HMGCR-positive patients, we identified 8 patients who were receiving PCSK9 inhibitors for hyperlipidemia.
|
31058470 |
2019 |
|
Hyperlipidemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis.
|
31779098 |
2019 |
|
Hyperlipidemia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Association of the variants and haplotypes in the DOCK7, PCSK9 and GALNT2 genes and the risk of hyperlipidaemia.
|
26493351 |
2016 |
|
Hyperlipidemia
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Among them, sparoside A (1), hanabiratakelide A (8), adenosine (11), and 5α,6α-epoxy-(22E,24R)-ergosta-8(14),22-diene-3β,7β-diol (14) exhibited potent inhibitory activities on PCSK9 mRNA expression, with IC<sub>50</sub> values of 20.07, 7.18, 18.46, and 8.23 μM, respectively (berberine, positive control, IC<sub>50</sub> = 8.04 μM), suggesting that compounds 1, 8, 11, and 14 are suitable for use in supplements to the statins for hyperlipidemia treatments.
|
28689410 |
2017 |
|
Hyperlipidemia
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The current study revealed that M3 and its structurally modified analog, A8, could regulate hepatic LDLR and PCSK9 expression to exert lipid-lowering effects via the ERK signal pathway, while A8 showed a stronger effect and might be a promising drug candidate against hyperlipidemia.
|
30335889 |
2018 |
|
Hyperlipidemia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Male and female endothelial cell-specific MR knockout mice and MR-intact littermates were randomized to high-fat-diet-induced obesity or obesity with hyperlipidemia induced by adeno-associated virus-based vector targeting transfer of the mutant stable form (DY mutation) of the human <i>PCSK9</i> (proprotein convertase subtilisin/kexin type 9) gene and compared with control diet.
|
29453308 |
2018 |
|
Hyperlipidemia
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Thus, adenoviral-mediated overexpression of PCSK9 in 24-h fasted mice results in massive hyperlipidemia, due to a striking increase in very-low-density lipoprotein (VLDL) triglycerides and apolipoprotein B100 hepatic output.
|
16794006 |
2006 |
|
Hyperlipidemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Plasma PCSK9 is associated with type III hyperlipidaemia.
|
24308640 |
2014 |
|
Hyperlipidemia
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
PCSK9 inhibitors are a class of lipid-lowering agents that significantly reduce low-density lipoprotein cholesterol (LDL-C) levels in patients with atherosclerotic cardiovascular disease and hyperlipidemia.
|
29511875 |
2018 |
|
Hyperlipidemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Vaccines Targeting PCSK9: A Promising Alternative to Passive Immunization with Monoclonal Antibodies in the Management of Hyperlipidaemia?
|
29737499 |
2018 |
|
Hyperlipidemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Single intravenous AAV-PCSK9(DY) injection is a fast, easy, and cost-effective approach, resulting in rapid and long-term sustained hyperlipidemia and atherosclerosis.
|
25341796 |
2015 |
|
Hyperlipidemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
However, treatments that target PCSK9 have shown striking early efficacy and promise to improve the lives of countless patients with hyperlipidemia and atherosclerosis.
|
30767742 |
2019 |
|
Hyperlipidemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors.
|
30828741 |
2019 |
|
Hyperlipidemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Evolocumab, a novel human monoclonal antibody, inhibits proprotein convertase subtilisin/kexin type 9, a protein that targets low-density lipoprotein-cholesterol (LDL-C) receptors for the treatment of hyperlipidemia.
|
29736889 |
2018 |
|
Hyperlipidemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
However, the function and mechanism of PCSK9 in neuronal apoptosis following hyperlipidemia remains to be elucidated.
|
28000893 |
2017 |
|
Hyperlipidemia
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
LDL-associated LPA was increased in plasma from high-fat Western diet-fed mice that are genetically prone to hyperlipidemia (LDL receptor knockout or activated proprotein convertase subtilisin/kexin type 9-overexpressing C57Bl6).
|
31484695 |
2019 |
|
Hyperlipidemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors.
|
29986989 |
2019 |
|
Hyperlipidemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
C57BL6/J mice were injected with AAVmPCSK9 and were fed with Western diet for 16 weeks, followed by reversal of hyperlipidemia by a diet switch to chow and treatment with a microsomal triglyceride transfer protein inhibitor (MTPi).
|
28291840 |
2017 |